Figure 1
From: Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study
Progression-free survival (A) for the intent-to-treat population (n=70) and the (B) subgroup analysis of patients with gallbladder (n=25) and non-gallbladder (n=45) tumours.
